| __timestamp | United Therapeutics Corporation | Viatris Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 381287000 | 1499100000 |
| Thursday, January 1, 2015 | 452612000 | 1923500000 |
| Friday, January 1, 2016 | 316800000 | 2351400000 |
| Sunday, January 1, 2017 | 330100000 | 2564000000 |
| Monday, January 1, 2018 | 265800000 | 2397300000 |
| Tuesday, January 1, 2019 | 336200000 | 2503400000 |
| Wednesday, January 1, 2020 | 423900000 | 3344600000 |
| Friday, January 1, 2021 | 467000000 | 4529200000 |
| Saturday, January 1, 2022 | 487000000 | 4179100000 |
| Sunday, January 1, 2023 | 477100000 | 4650100000 |
Data in motion
In the competitive landscape of the pharmaceutical industry, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. United Therapeutics Corporation and Viatris Inc. have taken different paths in optimizing these costs over the past decade.
From 2014 to 2023, United Therapeutics Corporation maintained a relatively stable SG&A expense trend, averaging around $394 million annually. Notably, their expenses peaked in 2022, reaching approximately $487 million, a 30% increase from their lowest point in 2018.
Viatris Inc., on the other hand, experienced more fluctuation, with SG&A expenses averaging $2.99 billion annually. Their costs surged by over 200% from 2014 to 2023, peaking at $4.65 billion in 2023.
This comparison highlights the contrasting strategies of these two companies in managing operational costs, reflecting their unique market positions and growth strategies.
Gilead Sciences, Inc. vs United Therapeutics Corporation: SG&A Expense Trends
Breaking Down SG&A Expenses: Zoetis Inc. vs Viatris Inc.
Operational Costs Compared: SG&A Analysis of United Therapeutics Corporation and Genmab A/S
United Therapeutics Corporation and Bio-Techne Corporation: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: United Therapeutics Corporation vs Lantheus Holdings, Inc.
SG&A Efficiency Analysis: Comparing United Therapeutics Corporation and Catalyst Pharmaceuticals, Inc.
Comparing SG&A Expenses: United Therapeutics Corporation vs Bausch Health Companies Inc. Trends and Insights
United Therapeutics Corporation vs Vericel Corporation: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing Viatris Inc. and BioMarin Pharmaceutical Inc.
Selling, General, and Administrative Costs: Viatris Inc. vs Ultragenyx Pharmaceutical Inc.
Operational Costs Compared: SG&A Analysis of Viatris Inc. and Corcept Therapeutics Incorporated
Cost Management Insights: SG&A Expenses for Viatris Inc. and BioCryst Pharmaceuticals, Inc.